Jennifer Panagoulias, RAC is the Chief Operating Officer of AS²Bio/MavriX Bio and the Head of Regulatory and Policy for the Foundation for Angelman Syndrome Therapeutics (FAST). Jennifer has worked in drug development for over 25 years, primarily focused on advancing global development programs for the treatment of rare neurological diseases. She spent 16 years in Regulatory Affairs at Genzyme where she held various roles, including Global Therapeutic Head, Regulatory Affairs Neurology.

At Genzyme, she supported global registration efforts for Myozyme (alglucosidase alfa), an enzyme replacement therapy for children and adults with Pompe disease—a rare, genetic, neuromuscular disorder. Jennifer has experience in working with global regulatory agencies including the US FDA, the European Medicines Agency, and the Pharmaceutical and Medical Device Agency in Japan. She has held key leadership roles in Regulatory Affairs and Quality Assurance supporting the development of oligonucleotide drugs at Wave Life Sciences and was part of the founding team at GeneTx Biotherapeutics advancing an investigational ASO specific for the treatment of Angelman syndrome. Jennifer serves as co-Director of the ABOM.